Article
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Nov 2014
Johnson Douglas B, Flaherty Keith T, Weber Jeffrey S, Infante Jeffrey R, Kim Kevin B, Kefford Richard F, Hamid Omid, Schuchter Lynn, Cebon Jonathan, Sharfman William H, McWilliams Robert R, Sznol Mario, Lawrence Donald P, Gibney Geoffrey T, Burris Howard A, Falchook Gerald S, Algazi Alain, Lewis Karl, Long Georgina V, Patel Kiran, Ibrahim Nageatte, Sun Peng, Little Shonda, Cunningham Elizabeth, Sosman Jeffrey A, Daud Adil, Gonzalez Rene
Abstract excerpt
PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had received prior BRAF inhibitor treatment. PATIENTS AND METHODS: In this open-label phase I/II study, we evaluated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.